Patrick Donnelly
Stock Analyst at Citigroup
(3.50)
# 879
Out of 5,147 analysts
371
Total ratings
48.74%
Success rate
4.97%
Average return
Main Sectors:
Stocks Rated by Patrick Donnelly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Maintains: Buy | $48 → $60 | $47.51 | +26.29% | 2 | Feb 26, 2026 | |
| SHC Sotera Health Company | Maintains: Buy | $21 → $23 | $16.25 | +41.54% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $135 → $150 | $93.90 | +59.74% | 12 | Feb 20, 2026 | |
| BRKR Bruker | Maintains: Neutral | $53 → $40 | $40.11 | -0.27% | 19 | Feb 13, 2026 | |
| QDEL QuidelOrtho | Maintains: Neutral | $23 → $30 | $22.74 | +31.93% | 7 | Feb 12, 2026 | |
| AVTR Avantor | Maintains: Neutral | $13 → $11 | $9.05 | +21.55% | 9 | Feb 12, 2026 | |
| DGX Quest Diagnostics | Maintains: Neutral | $190 → $215 | $211.91 | +1.46% | 12 | Feb 10, 2026 | |
| QGEN Qiagen | Maintains: Neutral | $55 → $55 | $49.80 | +10.44% | 15 | Feb 6, 2026 | |
| IQV IQVIA Holdings | Maintains: Neutral | $230 → $200 | $178.81 | +11.85% | 14 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $80 | $59.00 | +35.59% | 13 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $685 | $521.11 | +31.45% | 22 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $265 | $178.49 | +48.47% | 22 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $208.04 | +44.20% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 | $23.05 | -21.91% | 13 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $21 | $10.72 | +95.90% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $185 | $121.38 | +52.41% | 27 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,600 → $1,700 | $1,366.69 | +24.39% | 15 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $278.44 | +34.68% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $267.56 | +40.16% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $225 → $200 | $108.14 | +84.95% | 10 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $42 | $20.14 | +108.54% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $60 → $80 | $75.36 | +6.16% | 15 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $85 → $80 | $134.46 | -40.50% | 17 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $265 | $210.64 | +25.81% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $75 | $103.38 | -27.45% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $28 | $15.52 | +80.41% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $145 | $98.31 | +47.49% | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $265 → $300 | $319.38 | -6.07% | 24 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $3.15 | +185.71% | 6 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.75 → $2.75 | $2.29 | +20.09% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $250 → $260 | $289.12 | -10.07% | 11 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $9.06 | -33.77% | 4 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $28 → $32 | $4.61 | +594.14% | 2 | Nov 30, 2018 |
Medline
Feb 26, 2026
Maintains: Buy
Price Target: $48 → $60
Current: $47.51
Upside: +26.29%
Sotera Health Company
Feb 24, 2026
Maintains: Buy
Price Target: $21 → $23
Current: $16.25
Upside: +41.54%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $135 → $150
Current: $93.90
Upside: +59.74%
Bruker
Feb 13, 2026
Maintains: Neutral
Price Target: $53 → $40
Current: $40.11
Upside: -0.27%
QuidelOrtho
Feb 12, 2026
Maintains: Neutral
Price Target: $23 → $30
Current: $22.74
Upside: +31.93%
Avantor
Feb 12, 2026
Maintains: Neutral
Price Target: $13 → $11
Current: $9.05
Upside: +21.55%
Quest Diagnostics
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $215
Current: $211.91
Upside: +1.46%
Qiagen
Feb 6, 2026
Maintains: Neutral
Price Target: $55 → $55
Current: $49.80
Upside: +10.44%
IQVIA Holdings
Feb 6, 2026
Maintains: Neutral
Price Target: $230 → $200
Current: $178.81
Upside: +11.85%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $80
Current: $59.00
Upside: +35.59%
Jan 30, 2026
Maintains: Buy
Price Target: $660 → $685
Current: $521.11
Upside: +31.45%
Jan 16, 2026
Maintains: Buy
Price Target: $200 → $265
Current: $178.49
Upside: +48.47%
Jan 7, 2026
Initiates: Buy
Price Target: $300
Current: $208.04
Upside: +44.20%
Dec 11, 2025
Downgrades: Neutral
Price Target: $18
Current: $23.05
Upside: -21.91%
Dec 11, 2025
Upgrades: Buy
Price Target: $12 → $21
Current: $10.72
Upside: +95.90%
Nov 25, 2025
Maintains: Buy
Price Target: $165 → $185
Current: $121.38
Upside: +52.41%
Nov 10, 2025
Maintains: Buy
Price Target: $1,600 → $1,700
Current: $1,366.69
Upside: +24.39%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $278.44
Upside: +34.68%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $267.56
Upside: +40.16%
Aug 21, 2025
Downgrades: Neutral
Price Target: $225 → $200
Current: $108.14
Upside: +84.95%
Aug 13, 2025
Maintains: Buy
Price Target: $34 → $42
Current: $20.14
Upside: +108.54%
Jul 9, 2025
Upgrades: Buy
Price Target: $60 → $80
Current: $75.36
Upside: +6.16%
Jul 9, 2025
Downgrades: Sell
Price Target: $85 → $80
Current: $134.46
Upside: -40.50%
Jan 30, 2025
Maintains: Buy
Price Target: $285 → $265
Current: $210.64
Upside: +25.81%
Nov 6, 2024
Maintains: Buy
Price Target: $80 → $75
Current: $103.38
Upside: -27.45%
Aug 7, 2024
Maintains: Buy
Price Target: $30 → $28
Current: $15.52
Upside: +80.41%
Jul 30, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $98.31
Upside: +47.49%
Dec 11, 2023
Maintains: Neutral
Price Target: $265 → $300
Current: $319.38
Upside: -6.07%
Dec 11, 2023
Maintains: Buy
Price Target: $7 → $9
Current: $3.15
Upside: +185.71%
Aug 10, 2023
Maintains: Neutral
Price Target: $3.75 → $2.75
Current: $2.29
Upside: +20.09%
Feb 17, 2023
Maintains: Neutral
Price Target: $250 → $260
Current: $289.12
Upside: -10.07%
Nov 3, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $9.06
Upside: -33.77%
Nov 30, 2018
Upgrades: Neutral
Price Target: $28 → $32
Current: $4.61
Upside: +594.14%